NMN vs NR Compared on Human Trial Evidence

NMN vs NR at a Glance

No head-to-head trial comparing NMN and NR is in the sources we read. Both are orally administered NAD+ precursors. Human trials show blood NAD+ rises for NR in one 140-person trial and for NMN in several small trials, though some NMN trials found no significant change.

The evidence for NMN and NR differs in trial size and setup. The evidence base for NMN consists of multiple small clinical trials covering varied populations, dosing schedules, and physical performance measurements. In contrast, the primary evidence in the sources we read for NR comes from a single 140-participant trial that tested three doses plus placebo in a uniform population over eight weeks.

Study funding also separates the research on NMN and NR. The 2023 review covering NMN trials had authors who report no conflicts of interest. The 140-person NR trial was funded by ChromaDex (the maker of NIAGEN); two authors are ChromaDex employees and a third is an inventor of intellectual property licensed by ChromaDex and its chief scientific adviser. Neither precursor has established a verified therapeutic outcome for any human medical condition.

What the NMN Trials Show

A 2023 review published in Advances in Nutrition evaluated the human clinical record for NMN. The authors identified 10 published human clinical trials, alongside 13 completed but unpublished trials and 11 ongoing trials. The published NMN studies evaluated varied populations and dosing strategies:

• 30 healthy adults taking 250 mg daily for 12 weeks
• 32 overweight or obese adults aged 55 to 80 taking 1000 mg once or twice daily for 14 days
• 25 postmenopausal prediabetic women taking 250 mg daily for 10 weeks
• 48 recreational runners taking 300 mg, 600 mg, or 1200 mg daily for 6 weeks
• 108 overweight or obese adults aged 65 or older taking 250 mg daily for 12 weeks
• 31 healthy adults taking 1250 mg daily for 4 weeks

Biological results varied across these cohorts. Several studies reported increases in circulating NAD+, including a 2.57-fold rise in whole blood at 12 weeks with 250 mg daily. Other studies observed no significant change from baseline in whole blood NAD+ after 16 weeks of 250 mg daily. In the study of postmenopausal prediabetic women, NAD+ rose in peripheral blood mononuclear cells (PBMCs) and plasma, but researchers observed no rise in skeletal muscle tissue.

Clinical outcomes in NMN trials were preliminary and mixed. The trial in recreational runners showed dose-dependent improvements in aerobic capacity. Trials in older men noted improvements in gait speed and grip strength. The study in prediabetic women demonstrated roughly a 25% improvement in muscle insulin sensitivity. Two trials evaluating sleep quality found no significant differences, a 60-day 6-minute walk test showed a 6.5% improvement that was not statistically significant compared to placebo, and overall cognitive function remained unchanged. No human trial had tested skin effects, despite NMN skin-care marketing.

The review emphasized several limitations in the published studies. Eight of the published studies enrolled between 8 and 66 participants, mostly phase I research. The largest study enrolled 108 participants, which barely reached phase II scale. Younger participants were underrepresented, clinical endpoints were narrow, and the authors cautioned that long-term safety profiles is unknown.

What the NR Trial Shows

The human evidence in the sources we read for NR centers on a randomized, double-blind, placebo-controlled clinical trial published in Scientific Reports in 2019. This trial tested NIAGEN nicotinamide riboside chloride across 140 healthy overweight adults aged 40 to 60 with a body mass index (BMI) between 25 and 30. The investigation followed a 2-week run-in period followed by 56 days of daily supplementation, with seven participants who did not complete the protocol.

Participants were divided into four parallel groups of 35 individuals receiving placebo, 100 mg, 300 mg, or 1000 mg of NR daily. Researchers measured blood NAD+ levels at multiple intervals. At day 14, blood NAD+ increased above baseline by 22% in the 100 mg group, 51% in the 300 mg group, and 142% in the 1000 mg group. At day 56, blood NAD+ elevations were +10% (100 mg), +48% (300 mg), and +139% (1000 mg).

The paper's abstract presents a numerical range for NAD+ changes that gives a different range than the figures reported in its main results section. Readers evaluating exact dose curves should consult the published paper directly to inspect the complete primary tables. In this trial, higher doses produced higher percentage rises in blood NAD+.

The study also tracked safety parameters and secondary physiological metrics. Over the 56-day evaluation, 61 participants reported a total of 95 adverse events. The authors reported that no serious adverse events occurred and no participants reported flushing episodes. All adverse events resolved by the conclusion of the study, with types and severity similar across groups. Supplementation did not significantly raise low-density lipoprotein cholesterol (LDL-C) or plasma homocysteine levels, produced no differences in mean body weight, and did not evaluate insulin sensitivity.

Study sponsorship and author affiliations are documented in the publication. ChromaDex (the maker of NIAGEN) funded the study; two authors are ChromaDex employees and a third is an inventor of intellectual property licensed by ChromaDex and its chief scientific adviser.

Blood NAD+ Is Not the Same as Clinical Benefit

Raising blood NAD+ concentrations does not prove that a supplement improves human health or slows biological aging. The 2023 review in Advances in Nutrition explicitly points out that circulating blood NAD+ is not an established biomarker of whole-body NAD+ status. There is no consensus on what normal NAD+ levels are. When an individual consumes an oral precursor, increases in blood cells do not guarantee that target tissues experience meaningful changes. For instance, the NMN trial in postmenopausal prediabetic women demonstrated that while NAD+ rose in circulating plasma and PBMCs, skeletal muscle tissue showed no measurable increase. A blood test reflecting higher circulating levels may not translate to active metabolic changes in skeletal muscle tissue.

Neither precursor has demonstrated proven clinical outcomes in disease prevention, life extension, or chronic disease management. While endpoints such as gait speed, muscle insulin sensitivity, and aerobic capacity showed preliminary findings in NMN trials, these observations require confirmation in larger clinical trials. Until randomized trials connect biomarker increases directly to functional clinical outcomes, claims regarding anti-aging benefits remain unproven hypotheses.

Safety Signals and United States Regulatory Status

The review calls oral NMN generally safe, but notes toxicological data are limited and long-term safety is unknown. In the published NMN human studies, researchers observed no significant adverse effects or clinical symptoms, leading review authors to describe oral intake as generally safe. Toxicological data on NMN are limited, long-term safety is unknown, and the review notes no established upper intake level.

Some animal and cell studies raised possible concerns. The 2023 review cited animal and cellular studies indicating potential risks. In one mouse model, NMN administration supported axon degeneration. In another study, NMN administration was linked to a pro-inflammatory senescence secretory response that promoted tumor progression. While animal findings do not demonstrate identical harms in humans, they highlight the necessity of long-term safety trials.

The NR safety profile in the sources we read rests primarily on the 56-day ChromaDex trial. The study documented adverse events that resolved by study end, without serious complications, flushing, or significant elevations in homocysteine and LDL-C. An 8-week trial in 140 people cannot establish multi-year safety across diverse patient demographics.

The regulatory histories of NMN and NR in the United States followed different paths. According to trade reporting from Nutraceuticals World, in 2022 FDA said NMN had been authorized as an investigational new drug before it was marketed as a supplement, which precluded supplement sale; after citizen petitions and a lawsuit by the Natural Products Association, FDA in 2025 declared NMN lawful as a dietary supplement ingredient. On December 2, 2025, FDA reinstated its May 2022 good day letter to SyncoZymes acknowledging a new dietary ingredient notification with no objections. Check FDA's own records directly. ChromaDex submitted a GRAS notice for NIAGEN nicotinamide riboside chloride as a vitamin B3 source in specific foods. Covered foods include protein shakes, nutrition bars, gum, chews, and powdered beverages. The notice specifies a maximum concentration of 0.0057% by weight as consumed. The FDA response letter stated that FDA has no questions at this time. This GRAS notice is about use as a food ingredient, not an FDA finding that NR treats or prevents any condition.

Who Might Choose Each Supplement

Deciding between NMN and NR turns on evidence quality, cost, and regulatory status. Because neither precursor has demonstrated proven clinical outcomes, the choice turns on evidence quality, study sponsorship, cost, and regulatory status.

An individual might consider NMN because the review authors reported no conflicts of interest and trials evaluated functional endpoints, though findings were preliminary and mixed. The published human trials on NMN investigated measurable physiological tasks, such as aerobic capacity in runners, gait speed in older adults, and insulin sensitivity in prediabetic women. The authors of the 2023 review reported no conflicts of interest.

Conversely, a consumer might select NR if they prefer a unified, randomized, double-blind, placebo-controlled trial where higher doses had higher percentage rises. The 140-participant NR trial found blood NAD+ rises of 10%, 48%, and 139% at day 56, with no significant rise in LDL-C or plasma homocysteine. NR also has an FDA GRAS response letter for specific food uses.

Important commercial factors cannot be verified from the published sources we read. Retail pricing per daily dose, raw material purity, certified manufacturing standards, and third-party laboratory verification vary widely across supplement brands and are not documented in the scientific trial record. Check labels and ask a clinician directly.

Neither precursor should ever be used to treat any medical condition. Anyone who is pregnant, nursing, managing an active illness, or taking prescription medication should consult a licensed physician before considering either precursor. Ask a clinician before changing any medication. For additional reading on related compounds, see our guides on longevity supplements, NAD patches vs injections, and NAD peptides.

The Verdict: NMN or NR

Current scientific evidence does not justify declaring either NMN or NR superior for human health. Trials show blood NAD+ rises for NR and in several NMN studies, though some NMN trials found no significant change, and neither has proven clinical superiority, disease prevention, or life extension. In our review of the published trials, we found that neither option has proven clinical benefits.

This comparison is not for individuals seeking medical treatments for acute or chronic metabolic illnesses. Neither should replace medical interventions, balanced nutrition, or clinician-directed care. People with a medical condition should ask a clinician.

Our evaluation would change if researchers publish a rigorous head-to-head randomized trial comparing NMN and NR directly across identical clinical endpoints. A verdict shift would also follow if independent investigators replicate NR's dose-dependent findings without commercial sponsorship, if regulators establish a verified tolerable upper intake level for NMN, or if long-term trials establish clear clinical benefits beyond blood NAD+ levels.

Before introducing either compound into your routine, consult a qualified healthcare provider to discuss your metabolic profile and safety considerations. To examine your personal metabolic health markers, complete our assessment to prepare for an informed discussion with your clinician.